Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by End User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Clinical Trials by the Market Players for the Early Detection of Liver Cancer
4.1.1.2. Development of New Biomarkers for the Early Detection of Liver Cancer
4.1.2. Restraints
4.1.2.1. The High Cost of Liver Cancer Screening
4.1.3. Opportunity
4.1.3.1. Rising Demand for Point-Of-Care Testing (POCT) in Liver Cancer Diagnostics
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Test Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.1.2. Market Attractiveness Index, By Test Type
8.2. Alpha-fetoprotein (AFP) tumor marker test*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Laboratory Tests
8.3.1. Biomarker
8.3.1.1. Oncofetal and Glycoprotein Antigens
8.3.1.2. Enzymes and Isoenzymes
8.3.1.3. Growth Factors and Receptors
8.3.1.4. Molecular Markers
8.3.1.5. Pathological Biomarkers
8.3.2. Blood Tests
8.3.2.1. Liver function tests (LFTs)
8.3.2.2. Blood clotting tests
8.3.2.3. Kidney function tests
8.3.2.4. Complete blood count (CBC)
8.3.2.5. Blood chemistry tests and other tests
8.4. Biopsy
8.4.1. Fine-needle aspiration biopsy
8.4.2. Core needle biopsy
8.4.3. Laparoscopy
8.5. Imaging
8.5.1. Ultrasound
8.5.2. Computed tomography (CT)
8.5.3. Magnetic resonance imaging (MRI)
8.5.4. Angiography
8.5.5. Others
8.6. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Institutes
9.4. Diagnostic Laboratories
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.5.1. U.S.
10.2.5.2. Canada
10.2.5.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.5.1. Germany
10.3.5.2. U.K.
10.3.5.3. France
10.3.5.4. Italy
10.3.5.5. Spain
10.3.5.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.5.1. Brazil
10.4.5.2. Argentina
10.4.5.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. Company Profiles
12.1. Abbott Laboratories*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. F. Hoffmann-La Roche Ltd.
12.3. Qiagen N.V.
12.4. Thermo Fisher Scientific, Inc.
12.5. Siemens Healthineers
12.6. BD
12.7. Illumina, Inc.
12.8. Koninklijke Philips N.V
12.9. Epigenomics AG
12.10. Fujifilm Medical Systems U.S.A., Inc.
12.11. Sysmex Corporation
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us